SCHEMBL13625656

SCHEMBL13625656

CCOC(=O)c1cc(Cc2ccc(F)cc2)c[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.48
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 2/20 0.48
HPGD P15428 1/20 0.48
ALOX12 P18054 1/20 0.48
CCR6 P51684 1/20 0.48
HKDC1 Q2TB90 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
ALOX5 P09917 1/20 0.46
GABRA1 P14867 3/20 0.44
GABRB2 P47870 3/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
GABRB1 P18505 2/20 0.44
GABRA3 P34903 2/20 0.44
GABRP O00591 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1149496 0.89 DAO (0.50) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL12857949 0.86 MAPT (0.59) MAPTKDM4ELMNAKMT2AALDH1A1
SCHEMBL12858131 0.86 SMN1; SMN2 (0.57) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL23452374 0.84 GABRA1 (0.50) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL14791060 0.80 GABRA1 (0.50) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL1149247 0.80 ALDH1A1 (0.57) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL13625658 0.79 DAO (0.54) KDM4ELMNAALDH1A1HPGDRAB9A
SCHEMBL15287084 0.79 GABRP (0.49) MAPTKDM4ELMNAMEN1KMT2A
SCHEMBL1149560 0.78 GABRP (0.43) MAPTMEN1KMT2AALDH1A1HPGD
SCHEMBL5063289 0.77 GABRA1 (0.48) MAPTKDM4ELMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7615572-B2 4,5-substituted pyrazole-3-carboxylic acids/esters/salts; D-amino acid oxidase (DAAO) inhibitors; increase D-Serine level; reduce level of toxic products of D-Serine oxidation; activate N-methyl-D-aspartate NMDA-glutamate receptors; neuropathic agent, schizophrenia, Alzheimer's, anaxia SEPRACOR INC. (US) 2009-11-10 US disclosed
US-20090170916-A1 Pyrrole and Pyrazole DAAO Inhibitors SEPRACOR INC. (US) 2009-07-02 US disclosed
US-7488747-B2 Pyrrole and pyrazole DAAO inhibitors SEPRACOR INC. (US) 2009-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170916-A1 Pyrrole and Pyrazole DAAO Inhibitors DDO, DAO, SRR MAPT 1403/4885KDM4E 1764/4885LMNA 4759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.